Based on its current operating plans, Prime Medicine expects that its cash, cash equivalents and short-term investments as of September 30, 2022, together with the approximately $200 million in gross proceeds raised through its initial public offering in October 2022, will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2025.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRME:
- Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Prime Medicine initiated with an Equal Weight at Morgan Stanley
- Prime Medicine initiated with a Buy at Jefferies
- Prime Medicine initiated with a Neutral at Goldman Sachs
